Relaxo Footwears' Q3 Profit Slips 20% Amid Margin Squeeze, Costs

CONSUMER-PRODUCTS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Relaxo Footwears' Q3 Profit Slips 20% Amid Margin Squeeze, Costs
Overview

Relaxo Footwears reported flat Q3 FY26 revenue at Rs. 668 cr, but profit after tax plunged 19.6% YoY to Rs. 27 cr. EBITDA fell 16.8% with margins contracting 211 bps to 10.4%, hit by increased sales promotions and a one-time labour code cost. Nine-month FY26 revenue declined 6.8% YoY. Management cited cautious consumer spending and plans to focus on operational efficiencies.

📉 The Financial Deep Dive

Relaxo Footwears Limited announced its unadited financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26 and 9M FY26), revealing a mixed performance marked by stable top-line revenue but declining profitability.

The Numbers:

  • Q3 FY26: Revenue stood at Rs. 668 crores, a marginal increase of 0.2% year-on-year (YoY) against Rs. 667 crores in Q3 FY25. However, EBITDA declined by 16.8% YoY to Rs. 69 crores from Rs. 83 crores. The EBITDA margin contracted by 211 basis points to 10.4%. Profit After Tax (PAT) decreased by 19.6% YoY to Rs. 27 crores, with the PAT margin falling 98 basis points to 4.0%.
  • 9M FY26: Revenue decreased by 6.8% YoY to Rs. 1,951 crores. EBITDA was down 7.4% YoY at Rs. 250 crores, with an EBITDA margin of 12.8%. PAT saw a marginal decrease of 2.2% YoY to Rs. 112 crores, and the PAT margin was 5.7%.

The Quality:

The decline in profitability for both Q3 and 9M FY26 was primarily attributed to increased sales promotion initiatives and a one-time cost of Rs. 5.7 crores associated with the new labour code in Q3 FY26. This led to a clear compression in both EBITDA and PAT margins.

The Grill:

Management acknowledged a subdued operating environment and cautious consumer purchasing behaviour. While the company achieved stable Q3 revenue after sequential declines in prior quarters, specific forward-looking guidance numbers were not provided. The strategy moving forward focuses on strengthening backend processes, optimising the supply chain, enhancing operational efficiencies, and executing market strategies, including the 'Relaxo Parivaar' platform to improve distributor and retailer engagement. The absence of specific guidance numbers might leave investors seeking clearer short-term growth and margin targets.

Risks & Outlook:

  • Specific Risks: Continued cautious consumer spending, execution risks in cost optimisation measures, and navigating a competitive market landscape are key challenges.
  • The Forward View: Investors will be watching closely for the company's ability to translate its focus on operational efficiencies into improved profitability and margin expansion in the upcoming quarters. The effectiveness of distributor and retailer engagement initiatives will also be a key monitorable.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.